Article: CIMA LABS Announces First-Quarter Financial Results; Patient Enrollment Begins in OraVescent Fentanyl Phase III Clinical Trials.

Article: CEPHALON'S ORAVESCENT FENTANYL HITS PRIMARY ...
BIOWORLD Today;  May 6, 2005 ;     700+ words ... ... results from a Phase III study of Oravescent fentanyl, Cephalon Inc. said it is on track ... patients, and those treated with Oravescent fentanyl showed a statistically significant ... patients were titrated with a range of Oravescent fentanyl doses: 100 mcg, 200 mcg, 400 ...

Article: Licensing agreement signed for OraVescent Fentanyl.
Drug Week;  December 12, 2003 ;     534 words ... ... and development of its proprietary OraVescent Fentanyl medication for breakthrough cancer ... the opportunities that exist for OraVescent Fentanyl and look forward to the global development ... sublingual and buccal formulations of OraVescent Fentanyl. This article was prepared by Drug ...

Article: CIMA LABS Announces Successful End of Phase II Meeting with the ...
Business Wire;  December 10, 2003 ;     700+ words ... ... regarding the Company's proprietary OraVescent Fentanyl transmucosal dosage form under development ... We look forward to beginning our OraVescent Fentanyl Phase III clinical trials. This ... enrollment in CIMA's proposed Phase III OraVescent Fentanyl clinical trials. These statements ...

Article: CEPHALON FILES FOR CLEARANCE OF ORAVESCENT FENTANYL ...
BIOWORLD Today;  September 7, 2005 ;     700+ words ... ... Cephalon Inc. filed for regulatory approval of its OraVescent fentanyl tablet to treat breakthrough pain in cancer patients ... Actiq, another fentanyl-based product. Both Actiq and OraVescent fentanyl (OVF) are administered through transmucosal delivery ...

Article: Company reports on phase II meeting with FDA on Oravescent ...
Pharma Business Week;  January 5, 2004 ;     629 words ... ... Administration (FDA) regarding the company's proprietary OraVescent Fentanyl transmucosal dosage form under development for the treatment ... officer, commented: "We look forward to beginning our OraVescent Fentanyl phase III clinical trials. This will be an important ...

Article: Palio Communications has been selected by Cephalon as the ...
Medical Marketing & Media;  February 1, 2005 ;     700+ words ... ... selected by Cephalon as the professional agency of record for OraVescent fentanyl. Palio will develop and execute advertising and marketing ... including its commercial introduction in the U.S. OraVescent fentanyl is a fast-dissolving tablet currently in Phase III clinical ...

Article: CIMA LABS Announces Licensing Agreement with Taiho Pharmaceutical ...
Business Wire;  November 12, 2003 ;     700+ words ...Business Editors EDEN PRAIRIE, MinnBUSINESS WIRENov. 12, 2003 Exclusive Agreement Covers License and Development in Japan of CIMA's Proprietary Medication for Breakthrough Cancer Pain CIMA LABS INC. (NASDAQ: CIMA) announced today that it has signed an exclusive agreement with Taiho Pharmaceutical